Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4) for a newly hired non-executive officer, with a grant date of September 30, 2025.
The company granted 62,232 non-qualified stock options and 34,564 restricted stock units. The options have a ten-year term and an exercise price of $30.08, equal to the closing price on September 30, 2025. RSUs vest 25% annually over four years; options vest 25% after one year then monthly over the remaining three years (1/48th monthly), subject to continued employment.
Ultragenyx (NASDAQ: RARE) ha riportato un grant di equity per inducement ai sensi della Nasdaq Listing Rule 5635(c)(4) per un nuovo dirigente non esecutivo, con una data di grant del 30 settembre 2025.
L'azienda ha concesso 62.232 stock option non qualificate e 34.564 unità di azioni vincolate (RSU). Le opzioni hanno una scadenza di dieci anni e un prezzo di esercizio di $30,08, pari al prezzo di chiusura del 30 settembre 2025. Le RSU vestono al 25% all'anno per quattro anni; le opzioni vestono al 25% dopo un anno, poi mensilmente nei rimanenti tre anni (1/48 al mese), soggette al proseguimento dell'impiego.
Ultragenyx (NASDAQ: RARE) informó una concesión de acciones por inducción conforme a la Nasdaq Listing Rule 5635(c)(4) para un nuevo directivo no ejecutivo, con una fecha de asignación del 30 de septiembre de 2025.
La empresa concedió 62.232 opciones sobre acciones no calificadas y 34.564 unidades de acciones restringidas (RSU). Las opciones tienen un plazo de diez años y un precio de ejercicio de $30,08, igual al precio de cierre del 30 de septiembre de 2025. Las RSU se consolidan vesting al 25% anual durante cuatro años; las opciones se consolidan vesting al 25% tras un año y luego mensualmente durante los tres años restantes (1/48 al mes), sujeto a la continuidad del empleo.
Ultragenyx (NASDAQ: RARE)은 Nasdaq Listing Rule 5635(c)(4)에 따른 유도 보상 주식 부여를 새로 채용된 비임원(비경영진) 임원에게 보고했고, 부여일은 2025년 9월 30일이다.
회사는 62,232 비자격 주식옵션과 34,564 제한 주식 유닛(RSU)을 부여했다. 옵션의 만료기간은 10년이고 행사가는 $30.08로, 2025년 9월 30일 종가와 같다. RSU는 4년간 매년 25%씩 vest되며; 옵션은 1년 후 25%가 vest되고 남은 3년은 매월 1/48씩 vest되며(근속 조건 충족 시).
Ultragenyx (NASDAQ: RARE) a annoncé une dotation d’actions d’induction selon la règle 5635(c)(4) de Nasdaq pour un nouveau cadre non exécutif, avec une date d’attribution du 30 septembre 2025.
L’entreprise a accordé 62 232 options d’achat d’actions non qualifiées et 34 564 unités d’actions restreintes (RSU). Les options ont une durée de dix ans et un prix d’exercice de 30,08 dollars, équivalant au cours de clôture du 30 septembre 2025. Les RSU vestent à raison de 25 % par an sur quatre ans; les options se font vesting à 25 % après un an, puis mensuellement sur les trois années restantes (1/48e par mois), sous réserve de la poursuite de l’emploi.
Ultragenyx (NASDAQ: RARE) meldete eine Induktionsaktiengewährung gemäß Nasdaq Listing Rule 5635(c)(4) für eine neu eingestellte nicht leitende Führungskraft, mit einem Zuteilungsdatum vom 30. September 2025.
Das Unternehmen gewährte 62.232 nicht qualifizierte Aktienoptionen und 34.564 Restricted Stock Units (RSUs). Die Optionen haben eine Zehnjahreslaufzeit und einen Ausübungspreis von 30,08 USD, entsprechend dem Schlusskurs am 30. September 2025. Die RSUs vesten zu 25% jährlich über vier Jahre; Optionen vesten 25% nach einem Jahr und anschließend monatlich über die restlichen drei Jahre (1/48 pro Monat), vorbehaltlich der fortgesetzten Beschäftigung.
Ultragenyx (بورصة ناسداك: RARE) أبلغت عن منحة أسهم حافزة وفقاً لقاعدة الإدراج 5635(c)(4) في ناسداك لموظف جديد غير تنفيذي، مع تاريخ المنحة 30 سبتمبر 2025.
منحت الشركة 62,232 خيار أسهم غير مؤهلة و 34,564 وحدات أسهم مقيدة (RSUs). تعتبر الخيارات لمدة عشر سنوات ومعدل سعر الإضراب 30.08 دولار، وفقاً لسعر الإغلاق في 30 سبتمبر 2025. تستحق RSUs بنسبة 25% سنوياً على مدى أربع سنوات؛ تستحق الخيارات 25% بعد سنة ثم شهرياً خلال السنوات الثلاث المتبقية (1/48 شهرياً)، رهناً باستمرار التوظيف.
Ultragenyx (NASDAQ: RARE) 根据纳斯达克上市规则5635(c)(4)为一位新聘非执行官员披露了一个 诱导性股票授予，授予日期为2025年9月30日。
公司授予了 62,232份非合格股票期权和 34,564份受限股票单位（RSU）。期权有效期为 十年，行权价为 $30.08，等于2025年9月30日的收盘价。RSU按四年每年25% 的比例归属；期权在一年后首次归属25%，随后在剩余三年内按月递归归属（每月1/48），前提是持续任职。
- None.
- None.
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the company and 34,564 restricted stock units of the company’s common stock to one newly hired non-executive officer employee of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 30, 2025, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
What did Ultragenyx (RARE) announce on October 3, 2025 about inducement grants?
What is the exercise price and term for the RARE options granted on September 30, 2025?
How do the restricted stock units for the RARE inducement vest?
What is the vesting schedule for Ultragenyx's 62,232 stock options (RARE)?
Under which plan and Nasdaq rule were the RARE inducement awards granted?
